The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.00
Bid: 34.00
Ask: 36.00
Change: 1.50 (4.48%)
Spread: 2.00 (5.882%)
Open: 33.50
High: 36.00
Low: 33.00
Prev. Close: 33.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sierra Oncology to host call on Chk1 inhibitor

18 Sep 2017 12:00

RNS Number : 0247R
Sareum Holdings PLC
18 September 2017
 

 (AIM: SAR)

18 September 2017

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Sierra Oncology to host Key Opinion Leader call with Thomas Helleday, PhD on DNA Damage Response Targets, on Tuesday 19 September

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, will host a Key Opinion Leader call with Thomas Helleday, PhD on the topic of "DNA Damage Response Targets Beyond PARP" focusing on clinical stage DDR targets in oncology, including Checkpoint kinase 1 (Chk1), on Tuesday, September 19 at 10:30 am Eastern Time (3:30pm UK time) - details below.

SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of important cell cycle checkpoints and central mediator of the DNA damage Response (DDR) network. Sierra Oncology holds exclusive and worldwide rights for SRA737, having licensed the programme from Sareum's co-investment partner, the CRT Pioneer Fund, in September 2016. SRA737 is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.

The call will feature a presentation by distinguished scientist Thomas Helleday, PhD, the Torsten and Ragnar Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden, who will examine emerging data and current mechanistic understandings of the next generation of clinical stage DDR targets in oncology, including Chk1. In addition, he will review which drug targets are synergistic in combination with Chk1 inhibition, and also will discuss certain preclinical DDR targets currently generating interest in the field.

Sierra Oncology's Senior Vice President of Research, Christian Hassig, PhD, will provide a brief overview on the company's research and development strategy for SRA737, which has best-in-class potential and is currently in two Phase 1 clinical trials focused on enrolling patients with tumours identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality, as a monotherapy or in combination.

The Press release from Sierra Oncology can be found by clicking here

Dial-In & Webcast Information

Domestic: +1 800-289-0496

International: +1 719-325-4826

Conference ID: 8310106

Webcast: www.sierraoncology.com  

direct link: http://public.viavid.com/index.php?id=126208  

 

For further information, please contact: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

 Shabnam Bashir/ Mark Swallow/ David Dible 

 020 7282 9571

Notes for editors: 

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

- Ends -

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKVLBFDKFLBBL
Date   Source Headline
3rd Jun 201911:00 amRNSPrice Monitoring Extension
3rd Jun 20197:00 amRNSPositive SRA737 data presented at ASCO
16th May 20197:00 amRNSASCO abstracts for SRA737 published
8th May 201912:41 pmRNSSareum notes Sierra Oncology Q1 2019 Results
30th Apr 20197:00 amRNSSareum to Present at BioTrinity 2019 in London
23rd Apr 20197:00 amRNSSRA737 Phase I/IIa data to be presented at ASCO
2nd Apr 20197:00 amRNSPreclinical Data for SRA737 Presented at AACR 2019
12th Mar 20197:00 amRNSSareum Holdings PLC Issue of Options
4th Mar 20197:00 amRNSHALF-YEARLY RESULTS ENDED 31 DECEMBER 2018
28th Feb 20192:04 pmRNSSierra Oncology has reported its 2018 Results
28th Feb 20198:14 amRNSNew SRA737 preclin data to be presented at AACR
23rd Jan 20191:38 pmRNSSierra Oncology to present SRA737 at DDR Tx Summit
18th Dec 201812:35 pmRNSResults of AGM
18th Dec 20187:00 amRNSAGM Statement
30th Nov 201811:17 amRNSAmendment to Preclinical Efficacy Announcement
30th Nov 20187:45 amRNSPreclinical Efficacy for Immunotherapy Combination
15th Nov 201810:24 amRNSPreclinical Data for SRA737 in Ovarian Cancer
14th Nov 20187:00 amRNSAGM NOTICE
13th Nov 20187:00 amRNSDirectorate Change
8th Nov 201812:28 pmRNSSierra Oncology Q3 2018 Results
26th Oct 20187:00 amRNSCompletion of Placing
1st Oct 20187:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
27th Sep 20181:03 pmRNSNotice of Results
26th Sep 20187:00 amRNSTYK2/JAK1 selected for certain cancers
11th Sep 20187:00 amRNSPre-Close Trading Statement
10th Sep 20187:00 amRNSSelection of TYK2/JAK1 for autoimmune diseases
9th Aug 20181:15 pmRNSSareum notes Sierra Oncology Q2 2018 Results
11th Jul 20189:38 amRNSNotification of PCA Shareholding
15th Jun 20187:00 amRNSAdvisers
31st May 20187:00 amRNSSareum regains rights to Aurora+FLT3 inhibitors
10th May 201812:21 pmRNSSRA737 trial update in Sierra Oncology Q1 Results
24th Apr 20187:00 amRNSSareum to Present at BioTrinity 2018 in London
17th Apr 201812:45 pmRNSAACR 2018 Update
15th Mar 20187:00 amRNSLate-breaker abstract for SRA737 accepted for AACR
13th Mar 20187:00 amRNSInterim Results
27th Feb 201812:50 pmRNSSierra Oncology expands SRA737 development program
22nd Feb 20187:00 amRNSPreclinical synergy of sra737 and PARP inhibitor
13th Feb 20187:00 amRNSNotice of Interim Results
20th Dec 201711:00 amRNSIssue of Options
19th Dec 20177:00 amRNSPatent Grants in Japan & China for TYK2 Inhibitors
14th Dec 201711:01 amRNSResult of AGM
14th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSNotice of AGM and Annual Report & Accounts
14th Nov 201712:05 pmRNSPlacing
31st Oct 20177:00 amRNSSierra Reports Preclinical Data for Chk1 Inhibitor
19th Oct 20177:00 amRNSFinal Results
9th Oct 201712:00 pmRNSSierra Oncology host KOL Meeting on 12 Oct in NY
18th Sep 201712:00 pmRNSSierra Oncology to host call on Chk1 inhibitor
22nd Aug 20177:00 amRNSPre-Close Trading Statement
19th Jun 20177:00 amRNSSareum to Present at the ICCS 2017

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.